10/30/2024
5:04 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/24/2024
1:02 PM | BlackRock, Inc. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form SC 13G | |
10/22/2024
3:18 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:19 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:21 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:22 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:23 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
10/22/2024
3:17 PM | Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/18/2024
5:42 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:27 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:42 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:10 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:17 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
3:57 PM | Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:00 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024
4:06 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/15/2024
3:38 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/10/2024
7:36 PM | Ballal Rahul D. (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
7:38 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
7:39 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/09/2024
3:27 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/09/2024
3:16 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/08/2024
5:54 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/08/2024
5:56 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/08/2024
5:57 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/08/2024
5:58 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/04/2024
3:28 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/03/2024
5:43 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
5:44 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
5:45 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
5:47 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/01/2024
6:53 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/30/2024
3:19 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/18/2024
3:17 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/03/2024
4:43 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/29/2024
5:36 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/28/2024
6:48 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/19/2024
6:49 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/19/2024
3:32 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/19/2024
3:32 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2024
3:15 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
This Bull Market Indicator called NVDA at $116 (Ad) Every now and again we find an investment idea so incredible we can’t help but share.
And today is one of those rare days…
Except, today we won't be giving you insight on any one particular stock…
But rather, insight on a revolutionary new stock picking indicator…
In fact, within the last year, this indicator has become famous for a multitude of reasons…
But one of the biggest was because of the buy signal it issued on October 18th, 2022.
In fact, on that very day, it said to buy NVDA at $116.37…
Anyone who did would be sitting on a tremendously large return today…
But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here |
08/02/2024
6:23 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/02/2024
6:25 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/02/2024
6:26 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/02/2024
6:22 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/31/2024
6:31 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/31/2024
6:33 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/31/2024
3:30 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/31/2024
3:31 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/29/2024
5:12 PM | 5AM Ventures VI, L.P. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form SC 13D/A | |
07/29/2024
4:39 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/29/2024
3:15 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/25/2024
3:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/17/2024
6:25 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
4:37 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
4:34 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/15/2024
3:12 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/12/2024
3:48 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/12/2024
3:48 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/03/2024
3:31 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/01/2024
7:03 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/27/2024
3:35 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/27/2024
3:38 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/25/2024
2:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/20/2024
6:20 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
4:12 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
3:24 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/10/2024
5:46 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2024
4:54 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2024
4:56 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/29/2024
3:06 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 8-K/A | |
05/29/2024
3:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/28/2024
4:45 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/28/2024
4:29 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/20/2024
6:46 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/20/2024
4:03 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Gupta Rishi (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/17/2024
2:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/17/2024
2:11 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED CAPITAL LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/17/2024
2:04 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024
6:29 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
4:23 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024
4:23 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/14/2024
3:15 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/14/2024
3:10 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/13/2024
6:35 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/08/2024
7:40 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/07/2024
5:58 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2024
6:02 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2024
6:04 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/30/2024
11:15 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form EFFECT | |
04/30/2024
3:16 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 424B3 | |
This Bull Market Indicator called NVDA at $116 (Ad) Every now and again we find an investment idea so incredible we can’t help but share.
And today is one of those rare days…
Except, today we won't be giving you insight on any one particular stock…
But rather, insight on a revolutionary new stock picking indicator…
In fact, within the last year, this indicator has become famous for a multitude of reasons…
But one of the biggest was because of the buy signal it issued on October 18th, 2022.
In fact, on that very day, it said to buy NVDA at $116.37…
Anyone who did would be sitting on a tremendously large return today…
But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here |
04/29/2024
5:50 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/26/2024
3:11 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form DEFA14A | |
04/26/2024
3:16 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form ARS | |
04/18/2024
3:44 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
04/15/2024
6:02 PM | Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:03 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:04 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:05 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:06 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
